(3R)-4-[1-(3-chlorophenyl)-6-fluorocyclohexa-2,4-dien-1-yl]-2-(1-cyclohexyloxycarbonyloxyethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3R)-4-[1-(3-chlorophenyl)-6-fluorocyclohexa-2,4-dien-1-yl]-2-(1-cyclohexyloxycarbonyloxyethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• 化学式: C₃₀H₃₉ClFNO₇
• 分子量: 580.1
• InChiKey: NPHDXRQFDWSKHP-DUYFRWPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS
  申请人：Novartis AG

  公开号：EP2956464A1

  公开（公告）日：2015-12-23
• [EN] SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE BUTANOÏQUE DE BISPHÉNOL SUBSTITUÉS EN QUALITÉ D'INHIBITEURS DE NEP (ENDOPEPTIDASE NEUTRE)
  申请人：NOVARTIS AG

  公开号：WO2014126979A1

  公开（公告）日：2014-08-21

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.